At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 132 enrolled
Drug / intervention
Aliskirendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Blinded Endpoint, Multi-center, Cross-over Study to Evaluate the Effect of High and Low Sodium Diets on Reduction in Mean 24-hour Ambulatory Blood Pressure in Systolic Hypertensive Patients Treated With Aliskiren (300 mg)
In Brief
A Phase 4 clinical trial evaluating Aliskiren for Hypertension. Completed, enrolled 132 participants across 19 sites.
Detailed Summary
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedFeb 2007
Primary CompletionNov 2007
TodayJul 2026
First PostedFeb 28, 2007
Enrollment StartJan 1, 2007
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.3 years ago
Interventions
Aliskirendrug